Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot
Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide injectible, positioning itself as a leader in this evolving market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 8, 2024 Category: Pharmaceuticals Source Type: news
Liraglutide May Ease Peripheral Artery Disease in T2D Liraglutide May Ease Peripheral Artery Disease in T2D
The drug significantly increased peripheral perfusion over 6 months compared with conventional cardiovascular risk factor treatment.Medscape UK (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 19, 2024 Category: Cardiology Tags: Diabetes & Endocrinology Source Type: news
Slowing of Peripheral Artery Disease: Another Liraglutide Benefit?
(MedPage Today) -- Liraglutide (Victoza), a type 2 diabetes drug, may help prevent peripheral artery disease (PAD) progression, the small, open-label STARDUST trial suggested.
Over 6 months, adults with type 2 diabetes on subcutaneous liraglutide... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 14, 2024 Category: Cardiology Source Type: news
News at a glance: Protecting a queen, cell therapy for solid tumors, and a UV telescope
CONSERVATION
U.S. protects iconic marine snail
The queen conch, a large marine snail known for its showy shell and delectable flesh, has been added to the U.S. government’s list of species threatened with extinction. Scientists at the National Oceanic and Atmospheric Administration (NOAA) said the species (
Strombus gigas
, pictured), which is native to the Caribbean region and grows up to 35 centimeters long, needs protection because populations are sparse, scattered, and heavily overfished. NOAA’s listing decision, issued on 14 February, has no immediate impact but authorizes the age...
Source: ScienceNOW - February 22, 2024 Category: Science Source Type: news
Weight loss jabs such as Wegovy may treat drug addiction by slashing powerful cravings
Fentanyl addicts who were given liraglutide while in withdrawal saw their cravings reduced. (Source: Daily Express - Health)
Source: Daily Express - Health - February 19, 2024 Category: Consumer Health News Source Type: news
Salt Subs in Normal BP; Stroke Thrombectomy Without $$; Walmart's CVD Blood Test
(MedPage Today) -- Among commonly used glucose-lowering medications for type 2 diabetes, liraglutide (Victoza) was tied to a particularly robust reduction of cardiovascular events. (Circulation)
Fewer than half of Americans know their blood pressure... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 13, 2024 Category: Cardiology Source Type: news
Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent Effects
TUESDAY, Jan. 16, 2024 -- Use of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a study published online Oct. 24 in Diabetes.
Mona... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 16, 2024 Category: Pharmaceuticals Source Type: news
Science ’s 2023 Breakthrough of the Year: Weight loss drugs with a real shot at fighting obesity
Show / hide sections navigation
2023 Breakthrough of the Year
Runners-up
Breakdowns
Video
Obesity plays out as a private struggle and a public health crisis. In the United States, about 70% of adults are affected by excess weight, and in Europe that number is more than half. The stigma against fat can be crushing; its risks, life-threatening. Defined as a body mass index of at least 30, obesity is thought to power type 2 diabetes, heart disease, arthritis, fatty liver disease, and certain cancers.
Yet drug treatments...
Source: ScienceNOW - December 14, 2023 Category: Science Source Type: news
GLP-1 RAs Plus Bariatric Surgery:'Promising' for Obesity GLP-1 RAs Plus Bariatric Surgery:'Promising' for Obesity
Liraglutide combined with endoscopic bariatric therapy can provide weight loss on par with bariatric surgery alone, raising the question of whether the GLP-1 RAs might one day replace surgery.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 15, 2023 Category: Endocrinology Tags: Gastroenterology News Source Type: news
GLP-1 Agonists Linked to Higher Risk for GI Complications GLP-1 Agonists Linked to Higher Risk for GI Complications
Compared with naltrexone/bupropion for weight loss, semaglutide and liraglutide were associated with a higher risk for three adverse gastrointestinal outcomes.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 5, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
Weight-Loss Drugs Come With Serious Side Effects, According to a New Study
There’s been a surge in demand for a class of diabetes drugs that are now popular for their serendipitous byproduct: weight loss.
The drugs belong to a class called GLP-1 agonists and include semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus; tirzepatide, which is found in Mounjaro; and liraglutide, used in Victoza and Saxenda. While effective in helping people with diabetes to lose about 15% of their body weight, these drugs are also linked to some risk of gastrointestinal side effects, including inflammation in the pancreas and obstructions of the digestive system.
[time-brightcove not-tgx=”...
Source: TIME: Health - October 5, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
Liraglutide Fixes Learning Limit Tied to Insulin Resistance Liraglutide Fixes Learning Limit Tied to Insulin Resistance
A single dose of GLP-1 receptor agonist liraglutide produced short-term correction of a deficit in associative learning found in people with insulin insensitivity and obesity in a controlled study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Scientists hope weight-loss drugs could treat addiction and dementia
Medications with semaglutide such as Ozempic and Wegovy are being studied to see if they can help other conditionsThey have taken the celebrity world by storm as a slimming jab and become a vital tool for managing type 2 diabetes. Now drugs such as Ozempic are being researched to look at whether they could help conditions ranging from alcohol misuse to dementia.Ozempic, a type 2 diabetes medication, and Wegovy, which is licensed for weight loss, contain the drug semaglutide, while a similar drug, liraglutide, is available for both purposes under different brand names.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 21, 2023 Category: Science Authors: Nicola Davis Tags: Dementia Alcoholism Drugs Health Diabetes UK news Source Type: news
I've been on a weight-loss drug like Ozempic for nearly a DECADE. The good, bad and ugly, this is what you can expect
Danielle Payton, 33, from Florida, started taking diabetes injection Victoza (inset) in 2014. She lost nearly 100 pounds but worries people taking the drugs unnecessarily are causing shortages. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2023 Category: Consumer Health News Source Type: news
Poor Weight Loss After Bariatric Surgery? Liraglutide May Help Poor Weight Loss After Bariatric Surgery? Liraglutide May Help
Added weight loss with liraglutide is ' extremely welcomed, ' with new antiobesity medications being ' another effective tool in the toolbox for the treatment of severe obesity, ' say experts.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 26, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
